What happened with AUPH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Aurinia Pharmaceuticals’ business centers on LUPKYNIS (voclosporin), a treatment approved for adults with active lupus nephritis, the kidney inflammation caused by lupus. It is Aurinia’s only approved product, and product sales provide most of its revenue. In the United States, Aurinia’s own sales team markets the medicine, while specialty pharmacies and a specialty distributor buy it from the company. Revenue is heavily concentrated in two specialty-pharmacy customers, each contributing a substantial share.
Outside the United States, partner Otsuka markets LUPKYNIS in Japan, the European Union, the United Kingdom and Switzerland. Aurinia supplies Otsuka with inventory for European and Japanese markets at cost plus a margin, and earns royalties and milestone payments under its licensing agreement. Sales in these markets depend on Otsuka’s commercialization work.
The business depends on doctors prescribing LUPKYNIS and government programs and private insurers covering its cost; required discounts and rebates reduce what Aurinia receives. Supply also relies on Lonza as the sole source of the active drug ingredient and Catalent as the sole capsule manufacturer. Aurinia is developing aritinercept for autoimmune diseases, but it cannot market that drug without regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aurinia’s results hinge on U.S. LUPKYNIS uptake and patent protection, with Roche/Genentech, Otsuka and Lonza worth watching for competing GAZYVA, overseas commercialization and sole-source drug-substance supply, respectively.
GSK competes with Aurinia for lupus-nephritis patients, selling injectable BENLYSTA against Aurinia’s oral LUPKYNIS for adults with active disease. BENLYSTA’s performance in lupus nephritis is the part of GSK’s medicines business to watch for competitive pressure on LUPKYNIS.
Biogen has financial rights to injectable GAZYVA, which competes with Aurinia’s oral LUPKYNIS for lupus-nephritis patients, but Roche and its sublicensees market and distribute the medicine. For Aurinia holders, GAZYVA’s lupus-nephritis business matters more than Biogen’s broader drug sales.
Teva, which sells generic and innovative medicines, is seeking U.S. approval to sell generic LUPKYNIS and is defending Aurinia’s patent-infringement lawsuit. Watch the court rulings: they could determine when Teva can compete with Aurinia’s branded lupus-nephritis medicine.
Dr. Reddy’s, which sells branded and generic medicines for patients, is challenging Aurinia’s patent protection while seeking U.S. approval for generic LUPKYNIS. Its patent-case developments are a direct signal of whether Aurinia’s branded lupus-nephritis medicine could face competition before the asserted patents expire in December 2037.
Novartis sells prescription medicines and is developing ianalumab and FABHALTA for lupus nephritis, potentially competing for the patients treated with Aurinia’s LUPKYNIS. Watch ianalumab’s Phase 3 and FABHALTA’s Phase 2 progress in lupus nephritis rather than treating either as an approved competitor for that disease.
Vera Therapeutics competes with Aurinia’s autoimmune-drug pipeline rather than its current LUPKYNIS sales: it develops treatments targeting BAFF and APRIL and names Aurinia’s BCMA Fc-fusion program as a direct competitor to VT-109. Watch VT-109’s development; Vera had no approved products or product-sales revenue as of December 31, 2025.
Dr. Reddy's Laboratories Limited earningsRDY
Dr. Reddy’s report will show how its generics business is doing, but its challenge to LUPKYNIS depends on the patent case, not broad drug sales.
Look for specific disclosure about the generic business or the U.S. patent case; overall growth would not show that an application to copy LUPKYNIS is closer to approval. Concrete progress would make future generic competition more tangible for Aurinia’s branded drug, but would not establish an entry date; no such update would leave its current sales position without a new direct challenge signal.
Aurinia Pharmaceuticals Inc earningsThis company
Aurinia Pharmaceuticals depends on LUPKYNIS for lupus nephritis, and this report will show whether sales keep growing faster than the costs of making and delivering the drug.
Read LUPKYNIS product sales alongside cost of revenue, and check whether growth still comes from selling more cartons. Rising sales with slower cost growth would mean greater use is still translating into gross profit; flat sales or faster-rising costs would point to weaker growth or less efficient growth in Aurinia’s only approved product.
